CCCC
NASDAQ · Biotechnology
C4 Therapeutics Inc
$3.15
+0.05 (+1.61%)
Financial Highlights (FY 2026)
Revenue
51.68M
Net Income
-150,969,309
Gross Margin
—
Profit Margin
-292.1%
Rev Growth
+5.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 39.6% | 39.6% |
| Operating Margin | -320.5% | -288.5% | 28.2% | 22.3% |
| Profit Margin | -292.1% | -277.5% | 17.7% | 21.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 51.68M | 49.24M | 17.10M | 17.57M |
| Gross Profit | — | — | 6.77M | 6.96M |
| Operating Income | -165,655,987 | -142,058,492 | 4.82M | 3.92M |
| Net Income | -150,969,309 | -129,463,914 | 3.03M | 3.72M |
| Gross Margin | — | — | 39.6% | 39.6% |
| Operating Margin | -320.5% | -288.5% | 28.2% | 22.3% |
| Profit Margin | -292.1% | -277.5% | 17.7% | 21.2% |
| Rev Growth | +5.0% | +5.0% | +6.2% | +3.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 64.70M | 53.64M |
| Total Equity | — | — | 64.52M | 70.28M |
| D/E Ratio | — | — | 1.00 | 0.76 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -162,864,727 | -147,424,002 | 5.37M | 5.78M |
| Free Cash Flow | — | — | 3.54M | 3.04M |